The RNA therapeutics industry is witnessing unprecedented growth driven by advances in molecular biology and biotechnology, with increasing adoption in personalized medicine and rare disease treatment. This dynamic sector is reshaping drug development paradigms by enabling targeted therapies with high specificity and minimal side effects.

Market Size and Overview
The RNA Therapeutics Market is estimated to be valued at USD 4.2 Mn in 2026 and is expected to reach USD 160.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 68.2% from 2026 to 2033.

This rapid market growth underlines increasing demand for RNA-based solutions across oncology, infectious diseases, and genetic disorders. The RNA Therapeutics Market Report highlights growing investments in RNA delivery technologies and expanding pipeline products which augment the market scope over the forecast period.

Market Segments

The RNA therapeutics market is broadly segmented into:

- Therapeutic Type: Including mRNA therapeutics, siRNA therapeutics, and antisense RNA therapeutics. Among these, mRNA therapeutics dominate due to their proven efficacy in vaccine development, evidenced by recent COVID-19 vaccines. siRNA therapeutics are the fastest-growing segment, propelled by improved delivery systems and new approvals in rare genetic disorders.
- Application: Encompassing oncology, infectious diseases, autoimmune diseases, and rare diseases. Oncology remains the dominant application segment, driven by clinical-stage pipeline expansions, while infectious diseases are the fastest-growing sector, especially post-pandemic.
- End User: Hospitals, research institutes, and pharmaceutical companies. Pharmaceutical companies lead owing to their capacity for large-scale RNA therapeutic commercialization and partnerships focusing on RNA platforms.

‣ Get more insights on : RNA Therapeutics Market

‣ Get this Report in Japanese Language:  RNA治療薬市場

‣ Get this Report in Korean Language:   RNA치료제시장